Accuray (ARAY) Set to Announce Quarterly Earnings on Wednesday

Accuray (NASDAQ:ARAY - Get Free Report) is set to post its quarterly earnings results after the market closes on Wednesday, May 1st. Analysts expect Accuray to post earnings of ($0.01) per share for the quarter. Accuray has set its Q3 2024 guidance at EPS and its FY 2024 guidance at EPS.Individual interested in participating in the company's earnings conference call can do so using this link.

Accuray (NASDAQ:ARAY - Get Free Report) last announced its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.05). Accuray had a negative return on equity of 28.11% and a negative net margin of 3.25%. The firm had revenue of $107.24 million during the quarter, compared to the consensus estimate of $107.11 million. During the same period last year, the company earned ($0.02) EPS. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Accuray Trading Down 0.9 %

NASDAQ:ARAY traded down $0.02 during midday trading on Wednesday, hitting $2.20. The stock had a trading volume of 293,900 shares, compared to its average volume of 449,972. Accuray has a one year low of $2.10 and a one year high of $4.30. The company has a market capitalization of $218.17 million, a price-to-earnings ratio of -14.47 and a beta of 1.44. The stock has a 50-day moving average of $2.52 and a 200 day moving average of $2.65. The company has a quick ratio of 0.84, a current ratio of 1.58 and a debt-to-equity ratio of 3.53.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Roth Capital reissued a "buy" rating on shares of Accuray in a research note on Tuesday, February 13th. TheStreet cut Accuray from a "c-" rating to a "d+" rating in a research report on Wednesday, February 14th. Finally, Roth Mkm assumed coverage on Accuray in a research report on Tuesday, February 13th. They set a "buy" rating and a $9.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $8.25.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.